Literature DB >> 23624077

The type 2 anti-Müllerian hormone receptor has splice variants that are dominant-negative inhibitors.

Floriane M Imhoff1, Dee Yang, Suneeth F Mathew, Andrew N Clarkson, Yui Kawagishi, Warren P Tate, Kyoko Koishi, Ian S McLennan.   

Abstract

Anti-Müllerian hormone (AMH) has both paracrine and hormonal actions that occur at different AMH concentrations, and in cells with different densities of its specific receptor (Amhr2). This diversity is not explained by canonical AMH signaling. We report that Amhr2 has two splice variants: Amhr2Δ2 (AMH binding site) and Amhr2Δ9/10 (kinase domain). Both spliced variants inhibit AMH signaling in a reporter assay. The mRNA for the spliced variants was relatively less abundant than Amhr2 mRNA in all tissues. This suggests that the physiological function(s) of the receptor variants may be restricted to specific cellular/subcellular sites and/or to the transport of AMH.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624077     DOI: 10.1016/j.febslet.2013.04.014

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.

Authors:  Alba Rodriguez-Garcia; Prannda Sharma; Mathilde Poussin; Alina C Boesteanu; Nicholas G Minutolo; Sarah B Gitto; Dalia K Omran; Matthew K Robinson; Gregory P Adams; Fiona Simpkins; Daniel J Powell
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome.

Authors:  Lidija K Gorsic; Matthew Dapas; Richard S Legro; M Geoffrey Hayes; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

Review 3.  Molecular Mechanisms of AMH Signaling.

Authors:  James A Howard; Kaitlin N Hart; Thomas B Thompson
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

Review 4.  Molecular genetics of Müllerian duct formation, regression and differentiation.

Authors:  Rachel D Mullen; Richard R Behringer
Journal:  Sex Dev       Date:  2014-07-12       Impact factor: 1.824

5.  A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives.

Authors:  Yi Li; Lina Wei; Marie-Charlotte Meinsohn; Rana Suliman; Maeva Chauvin; Jim Berstler; Kate Hartland; Mark M Jensen; Natalie A Sicher; Nicholas Nagykery; Patricia K Donahoe; David Pepin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-05       Impact factor: 12.779

6.  Reconsidering the Polycystic Ovary Syndrome (PCOS).

Authors:  Norbert Gleicher; Sarah Darmon; Pasquale Patrizio; David H Barad
Journal:  Biomedicines       Date:  2022-06-25

7.  Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II.

Authors:  Cagri Sakalar; Suparna Mazumder; Justin M Johnson; Cengiz Z Altuntas; Ritika Jaini; Robert Aguilar; Sathyamangla V Naga Prasad; Denise C Connolly; Vincent K Tuohy
Journal:  J Immunol Res       Date:  2015-11-05       Impact factor: 4.818

8.  Mutational Analysis of the Putative Anti-Müllerian Hormone (AMH) Binding Interface on its Type II Receptor, AMHR2.

Authors:  Kaitlin N Hart; David Pépin; Magdalena Czepnik; Patricia K Donahoe; Thomas B Thompson
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.